AmerisourceBergen leaders on Friday focused on giving independent pharmacists the tools they need to learn, optimize and grow during the general session of ThoughtSpot 2014, AmerisourceBergen and Good Neighbor Pharmacy’s annual tradeshow.
Perrigo on Wednesday announced that it has filed an abbreviated new drug application with the Food and Drug Administration for desoximetasone topical spray 0.25%. The company also has notified Taro Pharmaceuticals U.S.A., the owner of the reference listed drug, of the filing.
DSN had an opportunity at McKesson ideaShare to talk to Eyad Farah, senior director of retail product development at McKesson U.S. Pharmaceutical, about McKesson’s digital strategy for retail pharmacy and helping pharmacies leverage mobile and digital technology to engage, support and retain patients.
Cardinal Health announced at its Retail Business Conference that nine pharmacy schools across the country will collectively receive $2 million in funding through the Cardinal Health Pharmacy Scholarship Program in 2014.
McKesson Pharmacy Systems and Automation launched its new Adherence Performance reporting tool, which uses pharmacy data to supply pharmacies with the data they need to make improvements on the adherence of their patient base, the company said.
Ateb, a privately held company that seeks ways to improve patient care and enhance pharmacy operations, announced that pharmacy veteran Mark Gregory, R. Ph., will join its team to assist with business development.
Fresh from Tuesday morning’s Health Mart Annual Meeting at 2014 McKesson ideaShare, attendees eagerly gathered to take part in the Health Mart University Live sessions that addressed key topics for independent pharmacy success.
After speaking at the Health Mart Annual Meeting Tuesday morning, Tony Willoughby, Health Mart’s chief pharmacist, sat down with DSN to talk about how pharmacies can drive adherence and excel in today’s changing healthcare environment.
Even before the official start of this year’s McKesson ideaShare conference, the Gaylord Palms Resort and Convention Center was buzzing with attendees eager to take advantage of the robust lineup of continuing education courses held on Sunday and Monday.
The Food and Drug Administration on Thursday announced the approval of Ruconest, a recombinant C1-Esterase inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema.